secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K/A
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0000950170-23-000232
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Biosciences discloses CFO Thomas Schaefer compensation: $260K base, 40% bonus target, 50,000 stock options
--------------------------------------------------------------------------------

- Base salary $260,000 per annum; target bonus 40% of base salary as per employment letter effective Jan 3, 2023.
- Granted stock options to purchase 50,000 shares vesting over 4 years with 1-year cliff under 2015 Omnibus Plan.
- Severance: 6-month base salary non-CIC; 12-month salary + 100% equity vesting if terminated within 12 months post-change-in-control.
- Employment is at-will; CIC agreement expires on third anniversary of effective date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017023000232/0000950170-23-000232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017023000232/rkda-20230103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer